Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ABBOTT INDIA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ABBOTT INDIA BIOCON /
ABBOTT INDIA
 
P/E (TTM) x 35.5 48.6 73.0% View Chart
P/BV x 4.5 15.9 28.3% View Chart
Dividend Yield % 0.2 0.4 50.5%  

Financials

 BIOCON    ABBOTT INDIA
EQUITY SHARE DATA
    BIOCON
Mar-19
ABBOTT INDIA
Mar-19
BIOCON /
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs7078,834 8.0%   
Low Rs5545,458 10.1%   
Sales per share (Unadj.) Rs91.91,731.1 5.3%  
Earnings per share (Unadj.) Rs16.7211.9 7.9%  
Cash flow per share (Unadj.) Rs24.2219.9 11.0%  
Dividends per share (Unadj.) Rs1.0065.00 1.5%  
Dividend yield (eoy) %0.20.9 17.4%  
Book value per share (Unadj.) Rs101.6945.2 10.8%  
Shares outstanding (eoy) m600.0021.25 2,823.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.94.1 166.2%   
Avg P/E ratio x37.733.7 111.9%  
P/CF ratio (eoy) x26.132.5 80.3%  
Price / Book Value ratio x6.27.6 82.1%  
Dividend payout %6.030.7 19.5%   
Avg Mkt Cap Rs m378,330151,848 249.2%   
No. of employees `0006.13.5 175.9%   
Total wages/salary Rs m11,6534,356 267.5%   
Avg. sales/employee Rs Th8,994.310,555.5 85.2%   
Avg. wages/employee Rs Th1,900.71,249.9 152.1%   
Avg. net profit/employee Rs Th1,635.31,292.2 126.6%   
INCOME DATA
Net Sales Rs m55,14436,786 149.9%  
Other income Rs m1,4441,133 127.5%   
Total revenues Rs m56,58837,919 149.2%   
Gross profit Rs m15,8836,047 262.6%  
Depreciation Rs m4,478169 2,646.6%   
Interest Rs m70923 3,151.1%   
Profit before tax Rs m12,1406,989 173.7%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1232,485 85.4%   
Profit after tax Rs m10,0264,503 222.6%  
Gross profit margin %28.816.4 175.2%  
Effective tax rate %17.535.6 49.2%   
Net profit margin %18.212.2 148.5%  
BALANCE SHEET DATA
Current assets Rs m48,22827,610 174.7%   
Current liabilities Rs m30,3768,569 354.5%   
Net working cap to sales %32.451.8 62.5%  
Current ratio x1.63.2 49.3%  
Inventory Days Days6860 113.4%  
Debtors Days Days8627 312.1%  
Net fixed assets Rs m64,1301,057 6,067.8%   
Share capital Rs m3,000213 1,411.8%   
"Free" reserves Rs m57,98019,873 291.7%   
Net worth Rs m60,98020,086 303.6%   
Long term debt Rs m15,7660-   
Total assets Rs m121,92429,409 414.6%  
Interest coverage x18.1311.6 5.8%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.3 36.2%   
Return on assets %8.815.4 57.2%  
Return on equity %16.422.4 73.3%  
Return on capital %16.834.9 48.0%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,506369 4,202.6%   
Fx outflow Rs m10,3994,918 211.4%   
Net fx Rs m5,107-4,549 -112.3%   
CASH FLOW
From Operations Rs m11,5464,991 231.3%  
From Investments Rs m-7,138-2,570 277.7%  
From Financial Activity Rs m-2,417-1,428 169.3%  
Net Cashflow Rs m2,103993 211.7%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 7.9 106.3%  
FIIs % 10.7 0.1 10,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.1 116.4%  
Shareholders   109,995 18,270 602.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SUN PHARMA  ORCHID PHARMA  SANOFI INDIA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 15, 2021 (Close)

TRACK BIOCON

BIOCON - VENUS REMEDIES COMPARISON

COMPARE BIOCON WITH

MARKET STATS